About Stoke Therapeutics, Inc.
https://www.stoketherapeutics.comStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.
CEO
Ian F. Smith
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 142
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Canaccord Genuity
Buy
BTIG
Buy
Needham
Buy
Chardan Capital
Buy
Wedbush
Outperform
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
ATP LIFE SCIENCE VENTURES, L.P.
Shares:17.16M
Value:$531.5M
FMR LLC
Shares:6.87M
Value:$212.61M
BLACKROCK, INC.
Shares:5.99M
Value:$185.43M
Summary
Showing Top 3 of 161
About Stoke Therapeutics, Inc.
https://www.stoketherapeutics.comStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $10.63M ▼ | $52.73M ▲ | $-38.35M ▼ | -360.68% ▼ | $-0.65 ▼ | $-38.63M ▼ |
| Q2-2025 | $13.82M ▼ | $41.12M ▼ | $-23.48M ▼ | -169.96% ▼ | $-0.4 ▼ | $-26.85M ▼ |
| Q1-2025 | $158.57M ▲ | $47.33M ▲ | $112.88M ▲ | 71.19% ▲ | $1.95 ▲ | $111.72M ▲ |
| Q4-2024 | $22.61M ▲ | $36.27M ▲ | $-10.48M ▲ | -46.35% ▲ | $-0.18 ▲ | $-13.13M ▲ |
| Q3-2024 | $4.89M | $34.9M | $-26.43M | -540.05% | $-0.47 | $-29.46M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $248.31M ▲ | $360.26M ▼ | $52.16M ▲ | $308.11M ▼ |
| Q2-2025 | $247.71M ▼ | $384.51M ▼ | $49.56M ▼ | $334.94M ▼ |
| Q1-2025 | $357.32M ▲ | $406.89M ▲ | $56.81M ▲ | $350.07M ▲ |
| Q4-2024 | $216.9M ▼ | $271.56M ▼ | $42.53M ▼ | $229.02M ▼ |
| Q3-2024 | $239.2M | $293.32M | $61.21M | $232.11M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-38.35M ▼ | $-30.37M ▼ | $9.09M ▲ | $3.12M ▲ | $-18.15M ▲ | $-30.5M ▼ |
| Q2-2025 | $-23.48M ▼ | $-25.42M ▼ | $-148.48M ▼ | $554K ▼ | $-173.34M ▼ | $-25.58M ▼ |
| Q1-2025 | $112.88M ▲ | $131.83M ▲ | $13.63M ▲ | $1.37M ▲ | $146.83M ▲ | $131.68M ▲ |
| Q4-2024 | $-10.48M ▲ | $-23.19M ▼ | $819K ▲ | $568K ▼ | $-21.81M ▲ | $-23.23M ▼ |
| Q3-2024 | $-26.43M | $-21.61M | $-30M | $8.16M | $-43.46M | $-21.72M |
CEO
Ian F. Smith
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 142
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Canaccord Genuity
Buy
BTIG
Buy
Needham
Buy
Chardan Capital
Buy
Wedbush
Outperform
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
ATP LIFE SCIENCE VENTURES, L.P.
Shares:17.16M
Value:$531.5M
FMR LLC
Shares:6.87M
Value:$212.61M
BLACKROCK, INC.
Shares:5.99M
Value:$185.43M
Summary
Showing Top 3 of 161